Deadline: 01-Jul-2026
This grant programme supports basic and translational scientific research investigating the biochemical and molecular mechanisms of TFPI (Tissue Factor Pathway Inhibitor) and marstacimab, including related anti-TFPI therapies. The goal is to strengthen foundational understanding of coagulation biology and improve knowledge of how these pathways regulate blood clotting.
The programme emphasizes innovative laboratory-based research in biochemistry, molecular biology, and pharmacology.
Scientific Background and Purpose
The programme focuses on advancing knowledge of:
- TFPI biology and its role in coagulation regulation
- Anti-TFPI monoclonal antibodies such as marstacimab
- Intrinsic and extrinsic coagulation cascade interactions
- Molecular regulation of clotting pathways in human tissues
The research aims to improve understanding of how coagulation mechanisms function at a molecular and cellular level.
Key Research Focus Areas
Eligible studies may explore:
- Molecular and cellular mechanisms of marstacimab–TFPI interactions
- Tissue factor and TFPI expression across different tissues
- Binding kinetics and biochemical properties of TFPI pathways
- Functional roles of TFPI isoforms and circulating pools
- Interaction of TFPI with intrinsic and extrinsic coagulation cascades
- Regulatory proteins such as Protein S and Protein C
- Pharmacology of anti-TFPI therapies with concomitant medications
- Basic biological mechanisms of coagulation regulation
The focus is on mechanistic, laboratory-based discovery research.
Geographic Eligibility
The grant is limited to institutions located in the following countries:
- Brazil
- China
- Germany
- Italy
- Japan
- Netherlands
- Saudi Arabia
- South Korea
- Spain
- Turkey
- United Kingdom
- United States
Only eligible-country institutions may apply.
Funding Details
Key funding parameters include:
- Maximum funding per project: USD 50,000
- Study duration: up to 1 year
- Optional support: study drug or compound support up to USD 50,000 (in addition to project funding)
- Funding type: competitive research grant
Projects must be completed within the one-year timeframe.
Eligibility Criteria
Eligibility is strictly institutional and includes:
- Applications must be submitted by organizations, not individuals
- Principal investigator must be affiliated with the applying institution
- PI must hold an advanced degree such as MD, PhD, or equivalent in fields like:
- Medicine
- Nursing
- Pharmacy
- Physiotherapy
- Social work (or related advanced qualifications)
- Institutions must be able to legally receive funding from Pfizer Inc.
Independent medical practice groups are not eligible.
Institutional Requirements
Additional requirements include:
- Only one lead requesting organization per application
- Multi-institution collaborations must define clear roles
- The lead institution must maintain primary responsibility
- All participating entities must have relevant scientific roles
- Funding compliance with institutional legal and administrative standards
Applicants must confirm eligibility to receive funds before submission.
How the Programme Works
The application process typically includes:
- Identifying a relevant TFPI or marstacimab research question
- Designing a mechanistic or molecular biology study
- Securing institutional approval and PI eligibility
- Preparing a structured research proposal and budget
- Submitting through the official funding channel
- Conducting a one-year experimental research project if approved
The programme prioritizes rigorous experimental design and scientific novelty.
Evaluation Criteria
Applications are assessed based on:
- Scientific merit and originality
- Relevance to TFPI and coagulation biology
- Strength of molecular or biochemical methodology
- Feasibility within a one-year timeframe
- Institutional research capability
- Potential to advance foundational biological understanding
High-quality mechanistic research is prioritized.
Common Mistakes to Avoid
Frequent issues in applications include:
- Submitting clinical or non-mechanistic studies outside scope
- Weak focus on TFPI or marstacimab pathways
- Unclear or incomplete molecular biology methodology
- Missing institutional eligibility confirmation for funding receipt
- Poorly defined roles in multi-institution collaborations
- Overly broad or non-specific research questions
Strong applications are focused, mechanistic, and experimentally rigorous.
Frequently Asked Questions
Q1. What is this research grant about?
It supports molecular and biochemical research on TFPI, marstacimab, and coagulation pathways.
Q2. What is the funding amount?
Up to USD 50,000 per project, plus optional study drug support of similar value.
Q3. How long is the project duration?
Up to one year.
Q4. Who can apply?
Eligible institutions in selected countries; individuals cannot apply directly.
Q5. What qualifications must the PI have?
An advanced degree such as MD, PhD, or equivalent in a relevant field.
Q6. Which countries are eligible?
Including the US, UK, Germany, Japan, China, Brazil, and several others listed in the programme.
Q7. What type of research is supported?
Basic molecular and biochemical studies on TFPI and coagulation mechanisms.
Conclusion
This competitive grant programme supports advanced molecular and biochemical research into TFPI and marstacimab pathways, aiming to deepen scientific understanding of blood coagulation mechanisms. By funding focused one-year mechanistic studies in eligible institutions, it promotes foundational discoveries that may inform future therapeutic developments in coagulation biology.
For more information, visit Pfizer.